Health and Fitness Health and Fitness
Mon, December 5, 2011
Sun, December 4, 2011
Fri, December 2, 2011
Thu, December 1, 2011
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011

Gilman Law LLP Announces Securities Fraud Lawsuit Against Hospira, Inc.


//health-fitness.news-articles.net/content/2011/ .. ecurities-fraud-lawsuit-against-hospira-inc.html
Published in Health and Fitness on Monday, November 28th 2011 at 14:21 GMT by Market Wire   Print publication without navigation


November 28, 2011 17:14 ET

Gilman Law LLP Announces Securities Fraud Lawsuit Against Hospira, Inc.

BOSTON, MA--(Marketwire - Nov 28, 2011) - [ Gilman Law LLP ], a leading national securities law firm, is actively investigating shareholder allegations that [ Hospira, Inc ]. ("Hospira") and certain of its officers and directors made materially false and misleading statements or failed to disclose material information related to the company's business and operations in violation of the Securities Exchange Act of 1934.

A shareholder class action lawsuit was commenced in the United States District Court for the Northern District of Illinois. If you purchased or otherwise acquired shares of Hospira, Inc. (NYSE: [ HSP ]) between March 24, 2009 and October 17, 2011 ("Class Period"), and either lost money on the transaction or still hold the shares, you may contact Gilman Law LLP by January 20, 2012 to discuss your rights, including as to recovery of your losses or to obtain additional information.

Hospira's Allegedly Issued False and Misleading Information

Hospira is a global specialty pharmaceutical and medication delivery company that specializes in injectable drugs and infusion technologies. The complaint alleges that during the Class Period, Hospira failed to disclose that the Company suffered from extensive quality control issues which undermined both the viability of and the supposed financial savings that would be generated by Project Fuel. Project Fuel is a program designed to optimize Hospira's operations and increase shareholder value. Hospira allegedly was also unable to remedy problems indentified in FDA Warning Letters related to Hospira's infusion pumps, quality control deficiencies and manufacturing weaknesses.

Due to the ongoing FDA investigation, the production at the Rocky Mount, North Carolina manufacturing plant, which accounts for approximately 25% of the Company's sales, was severely impacted.

On October 18, 2011, the Company announced disappointing preliminary third quarter financial results and lower than expected full-year guidance. As a result of this news, Hospira's common stock fell $7.85 per share to close at $29.51 per share of October 18, 2011.

Gilman Law has extensive experience representing both individual and institutional investors in securities class action suits. For a free evaluation of your case or to obtain additional information, please visit [ http://investment-losses.com/ ] or CALL TOLL FREE (888) 252-0048.



Publication Contributing Sources